Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $28.24, for a total transaction of $5,648,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,647,546 shares of the company’s stock, valued at approximately $46,526,699.04. This represents a 10.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Friday, February 13th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $26.49, for a total transaction of $5,298,000.00.
• On Monday, January 12th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $21.92, for a total transaction of $4,384,000.00.
• On Wednesday, December 24th, Eric Venker sold 75,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.53, for a total transaction of $1,689,750.00.
• On Tuesday, December 23rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.45, for a total transaction of $4,490,000.00.

Roivant Sciences Stock Down 0.4%

Shares of NASDAQ:ROIV opened at $27.70 on Friday. The company has a market cap of $19.82 billion, a PE ratio of -23.68 and a beta of 1.17. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $30.33. The firm has a 50-day simple moving average of $25.92 and a 200 day simple moving average of $21.19.

Analysts Set New Price Targets

Several analysts recently issued reports on ROIV shares. Citigroup raised their price target on Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, February 10th. HC Wainwright upped their price objective on Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Leerink Partners raised their target price on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a report on Wednesday, March 4th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.50.

Institutional Trading of Roivant Sciences

Hedge funds have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. grew its stake in shares of Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares in the last quarter. Jones Financial Companies Lllp raised its stake in shares of Roivant Sciences by 226.0% during the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after purchasing an additional 1,148 shares in the last quarter. Allworth Financial LP raised its stake in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares in the last quarter. Bessemer Group Inc. lifted its holdings in Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares during the period. Finally, Kestra Advisory Services LLC acquired a new stake in Roivant Sciences in the fourth quarter worth about $47,000. Institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.